The US, UK, Japan, and EU countries have agreed to purchase 1.3 billion doses of the coronavirus vaccine, which has not yet been created. This is reported by Bloomberg with reference to a study by the analytical company Airfinity.
For example, the US and UK signed an agreement with Sanofi and GlaxoSmithKline Plc, and Japan signed an agreement with Pfizer. The European Union is also “aggressive” on purchases, the Agency notes but does not specify with whom European countries have signed a contract.
Thus, although the effectiveness of vaccines against the new type of virus has not yet been proven, a significant number of them are already reserved by rich countries and the number of transactions is likely to grow. Analysts say that 7.8 billion people may not have enough doses and poor states will be “last in line.”
A similar situation was in 2009 when rich countries monopolized the supply of swine flu vaccine.
An outbreak of unknown pneumonia began in the Chinese city of Wuhan at the end of December last year. As it turned out, the causative agent of the disease was a new type of coronavirus; later the disease was officially named COVID-19.